Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activityNicola J. Curtis, Susan E. Critchlow|Oncotarget|2017Cited by 155